JOMMI, CLAUDIO
JOMMI, CLAUDIO
Dipartimento di Scienze del Farmaco
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system
2021-01-01 Riva, S.; Efficace, F.; Di Maio, M.; Bryce, J.; Del Campo, L.; De Lorenzo, F.; Frontini, L.; Giannarelli, D.; Gitto, L.; Iannelli, E.; Jommi, C.; Montesarchio, V.; Traclo, F.; Vaccaro, C. M.; Arenare, L.; Canzanella, G.; Gimigliano, A.; Romano, F.; Savio, A.; Sparavigna, L.; Piccirillo, M. C.; Guizzaro, L.; Gallo, C.; Perrone, F.
Accordi di managed market entry (risk-sharing): razionale e tendenze evolutive nel SSN
2012-01-01 Jommi, Claudio
Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions
2016-01-01 Costa, F.; Armeni, P.; Otto, M. H.; Amoroso, N.; Jommi, C.
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration
2022-01-01 Finch, Aureliano Paolo; Meregaglia, Michela; Ciani, Oriana; Roudijk, Bram; Jommi, Claudio
An Introduction to Economic Evaluation of Health Care Programs
2017-01-01 Jommi, C.
An overview of market access agreements
2016-01-01 Toumi, M.; Zard, J.; Abdallah, I. B.; Jommi, C.; Cohen, J.
Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale
2013-01-01 Jommi, Claudio; A., Iorio; L., Crippa; A., Gelera; G., Senatore
Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel
2024-01-01 Jommi, Claudio; Patarnello, Francesca; Bianchi, Cosetta; Buzzetti, Giuliano
Biosimilari
2010-01-01 Jommi, Claudio
Biosimilari
2010-01-01 Jommi, Claudio
Biosimilari. Aspetti Economici e prospettive per il mercato italiano
2010-01-01 Jommi, Claudio
Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital
2014-01-01 Costa, E.; Biasi, V.; Concia, E.; Jommi, C.; Lattuada, E.; Manfre, S.; Venturini, F.; Lanzafame, M.
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
2018-01-01 Rognoni, Carla; Bertolani, Arianna; Jommi, Claudio
CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions
2022-01-01 Jommi, C.; Bramanti, S.; Pani, M.; Ghirardini, A.; Santoro, A.
Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study
2018-01-01 Cozzolino, M.; Bolasco, P.; Ronco, C.; Conte, G.; Mene, P.; Mereu, M. C.; Di Luca, M.; Roccatello, D.; Rosati, A.; Jommi, C.; Costanzo, A. M.; Gualberti, G.; Di Luzio Paparatti, U.; Remuzzi, G.
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
2023-01-01 Canales Albendea, Miguel Á.; Canonico, Pier Luigi; Cartron, Guillaume; Deiters, Barthold; Jommi, Claudio; Marks, Reinhard; Rioufol, Catherine; Sancho Cia, Juan M.; Santoro, Armando; Wagner-Drouet, Eva M.
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
2023-01-01 Arenare, L.; Porta, C.; Barberio, D.; Terzolo, S.; Zagonel, V.; Pisconti, S.; Del Mastro, L.; Pinto, C.; Bilancia, D.; Cinieri, S.; Rizzo, M.; Migliaccio, G.; Montesarchio, V.; Del Campo, L.; De Lorenzo, F.; Iannelli, E.; Traclò, F.; Gitto, L.; Vaccaro, M. C.; Frontini, L.; Giannarelli, D.; Bryce, J.; Piccirillo, M. C.; Jommi, C.; Efficace, F.; Riva, S.; Di Maio, M.; Gallo, C.; Perrone, F.
Content validity of the EQ-HWB and EQ-HWB-S in a sample of Italian patients, informal caregivers and members of the general public
2024-01-01 Masutti, Sara; Falivena, Camilla; Purba, Fredrick Dermawan; Jommi, Claudio; Mukuria, Clara; Finch, Aureliano Paolo
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
2024-01-01 Cavallo, Maria Caterina; Cavazza, Marianna; Bonifazi, Francesca; Casadei, Beatrice; Cutini, Ilaria; Tonietti, Barbara; Saccardi, Riccardo; Zinzani, Pierluigi; Jommi, Claudio
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service
2020-01-01 Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Grossi, F.; Costa, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system | 1-gen-2021 | Riva, S.; Efficace, F.; Di Maio, M.; Bryce, J.; Del Campo, L.; De Lorenzo, F.; Frontini, L.; Giannarelli, D.; Gitto, L.; Iannelli, E.; Jommi, C.; Montesarchio, V.; Traclo, F.; Vaccaro, C. M.; Arenare, L.; Canzanella, G.; Gimigliano, A.; Romano, F.; Savio, A.; Sparavigna, L.; Piccirillo, M. C.; Guizzaro, L.; Gallo, C.; Perrone, F. | |
| Accordi di managed market entry (risk-sharing): razionale e tendenze evolutive nel SSN | 1-gen-2012 | Jommi, Claudio | |
| Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions | 1-gen-2016 | Costa, F.; Armeni, P.; Otto, M. H.; Amoroso, N.; Jommi, C. | |
| An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration | 1-gen-2022 | Finch, Aureliano Paolo; Meregaglia, Michela; Ciani, Oriana; Roudijk, Bram; Jommi, Claudio | |
| An Introduction to Economic Evaluation of Health Care Programs | 1-gen-2017 | Jommi, C. | |
| An overview of market access agreements | 1-gen-2016 | Toumi, M.; Zard, J.; Abdallah, I. B.; Jommi, C.; Cohen, J. | |
| Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale | 1-gen-2013 | Jommi, Claudio; A., Iorio; L., Crippa; A., Gelera; G., Senatore | |
| Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel | 1-gen-2024 | Jommi, Claudio; Patarnello, Francesca; Bianchi, Cosetta; Buzzetti, Giuliano | |
| Biosimilari | 1-gen-2010 | Jommi, Claudio | |
| Biosimilari | 1-gen-2010 | Jommi, Claudio | |
| Biosimilari. Aspetti Economici e prospettive per il mercato italiano | 1-gen-2010 | Jommi, Claudio | |
| Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital | 1-gen-2014 | Costa, E.; Biasi, V.; Concia, E.; Jommi, C.; Lattuada, E.; Manfre, S.; Venturini, F.; Lanzafame, M. | |
| Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives | 1-gen-2018 | Rognoni, Carla; Bertolani, Arianna; Jommi, Claudio | |
| CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions | 1-gen-2022 | Jommi, C.; Bramanti, S.; Pani, M.; Ghirardini, A.; Santoro, A. | |
| Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study | 1-gen-2018 | Cozzolino, M.; Bolasco, P.; Ronco, C.; Conte, G.; Mene, P.; Mereu, M. C.; Di Luca, M.; Roccatello, D.; Rosati, A.; Jommi, C.; Costanzo, A. M.; Gualberti, G.; Di Luzio Paparatti, U.; Remuzzi, G. | |
| Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries | 1-gen-2023 | Canales Albendea, Miguel Á.; Canonico, Pier Luigi; Cartron, Guillaume; Deiters, Barthold; Jommi, Claudio; Marks, Reinhard; Rioufol, Catherine; Sancho Cia, Juan M.; Santoro, Armando; Wagner-Drouet, Eva M. | |
| Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients | 1-gen-2023 | Arenare, L.; Porta, C.; Barberio, D.; Terzolo, S.; Zagonel, V.; Pisconti, S.; Del Mastro, L.; Pinto, C.; Bilancia, D.; Cinieri, S.; Rizzo, M.; Migliaccio, G.; Montesarchio, V.; Del Campo, L.; De Lorenzo, F.; Iannelli, E.; Traclò, F.; Gitto, L.; Vaccaro, M. C.; Frontini, L.; Giannarelli, D.; Bryce, J.; Piccirillo, M. C.; Jommi, C.; Efficace, F.; Riva, S.; Di Maio, M.; Gallo, C.; Perrone, F. | |
| Content validity of the EQ-HWB and EQ-HWB-S in a sample of Italian patients, informal caregivers and members of the general public | 1-gen-2024 | Masutti, Sara; Falivena, Camilla; Purba, Fredrick Dermawan; Jommi, Claudio; Mukuria, Clara; Finch, Aureliano Paolo | |
| Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study | 1-gen-2024 | Cavallo, Maria Caterina; Cavazza, Marianna; Bonifazi, Francesca; Casadei, Beatrice; Cutini, Ilaria; Tonietti, Barbara; Saccardi, Riccardo; Zinzani, Pierluigi; Jommi, Claudio | |
| Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service | 1-gen-2020 | Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Grossi, F.; Costa, F. |